Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe,Canada and the US

Abstract

Background

Here, we aimed to evaluate regional differences in all-cause, AIDS- and non-AIDS-related mortality in HIV-positive men and women started on combination antiretroviral therapy (cART) in Europe, Canada and the US.

Methods

The ART Cohort Collaboration (ART-CC) combines 19 cohorts of individuals started on cART in Europe and North America (NA). We analysed patients infected via injecting drug use (IDU) or heterosexual sex using Cox proportional hazards models.

Results

A total of 32,443 European (45.9% women), 1,162 (32.5% women) Canadian and 2,721 (15.5% women) US patients were included. In Europe and NA, women were younger, more likely to have acquired HIV heterosexually, be AIDS-free and have higher CD4⁺ T-cell counts and lower HIV-1 RNA at baseline. European women had lower rates of all-cause (adjusted hazard ratio: 0.76; 95% CI 0.68, 0.84) and non-AIDS mortality (0.67; 0.57, 0.78) than men, but AIDS-mortality rates were similar (0.90; 0.75, 1.09). Women had lower mortality due to non-AIDS infections (0.6 versus 1.3 per 1,000 person-years), liver diseases (0.4 versus 1.7), non-AIDS malignancies (0.6 versus 2.0) and cardiovascular diseases (0.6 versus 1.0). Between-sex differences in all-cause mortality were larger in heterosexuals (0.70; 0.61, 0.80) than in IDU (0.88; 0.73, 1.05; interaction P-value =0.043). No sex differences in all-cause mortality were found in Canada (hazard ratio women 1.13; 0.82, 1.56) or US (hazard ratio women 1.12; 0.79, 1.58).

Conclusions

The increasing importance of non-AIDS mortality is leading to emergent sex differences among HIV-positive patients in Europe, as in the general population. Despite the better clinical characteristics at cART initiation, women in NA had similar mortality to men.

References

Waldron

Recent trends in sex mortality ratios for adults in developed countries.

Soc Sci Med 1993; 36: 451–462.

Gjonça

, Tomassini

, Toson

, Smallwood

Sex differences in mortality, a comparison of the United Kingdom and other developed countries.

Health Stat Q 2005; 26: 6–16.

Oksuzyan

, Crimmins

, Saito

, O'Rand

, Vaupel

J.W.

, Christensen

Cross-national comparison of sex differences in health and mortality in Denmark, Japan and the US.

Eur J Epidemiol 2010; 25: 471–480.

Barford

, Dorling

, Smith

, Shaw

Life expectancy: women now on top everywhere.

BMJ 2006; 332: 808.

Palella

F.J.

Jr. , Delaney

K.M.

, Moorman

A.C.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

N Engl J Med 1998; 338: 853–860.

Mocroft

, Lederberger

, Katlama

Decline in the AIDS death rates in the EuroSIDA study: an observational study.

Lancet 2003; 362: 22–29.

Weber

, Ruppik

, Rickenbach

Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study.

HIV Med 2013; 14: 195–207.

Poundstone

K.E.

, Chaisson

R.E.

, Moore

R.D.

Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy.

AIDS 2001; 15: 1115–1123.

Hessol

N.A.

, Kalinowski

, Benning

Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study.

Clin Infect Dis 2007; 44: 287–294.

10.

Lemly

D.C.

, Shepherd

B.E.

, Hulgan

Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

J Infect Dis 2009; 199: 991–998.

11.

Mocroft

, Gill

M.J.

, Davidson

, Phillips

A.N.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

J Acquir Immune Defic Syndr 2000; 24: 475–482.

12.

Jarrin

, Geskus

, Bhaskaran

Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.

Am J Epidemiol 2008; 168: 532–540.

13.

García de la Hera

, Ferreros

, del Amo

Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.

J Epidemiol Community Health 2004; 58: 944–950.

14.

Pérez-Hoyos

, del Amo

, Muga

Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.

AIDS 2003; 17: 353–359.

15.

Porter

, Babiker

, Bhaskaran

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

Lancet 2003; 362: 1267–1274.

16.

Pezzotti

, Dorrucci

, Donisi

Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART).

Epidemiol Prev 2003; 27: 348–355.

17.

Johnson

L.F.

, Mossong

, Dorrington

R.E.

Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.

PLoS Med 2013; 10: e1001418.

18.

Egger

, May

, Chene

Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Lancet 2002; 360: 119–129.

19.

May

M.T.

, Ingle

S.M.

, Costagliola

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).

Int J Epidemiol 2013; 43: 691–702.

20.

Antiretroviral Therapy Cohort Collaboration.

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.

Clin Infect Dis 2010; 50: 1387–1396.

21.

Fine

J.P.

, Gray

R.J.

A proportional hazards model for the subdistribution of a competing risk.

J Am Stat Assoc 1999; 94: 496–509.

22.

Mathers

C.D.

, Boerma

, Ma Fat

Global and regional causes of death.

Br Med Bull 2009; 92: 7–32.

23.

Pampel

Forecasting sex differences in mortality in high income nations: the contribution of smoking.

Demogr Res 2005; 13: 455–484.

24.

Del Amo

, Likatavicius

, Perez-Cachafeiro

The epidemiology of HIV and AIDS reports in migrants in the 27 European Union countries, Norway and Iceland: 1999-2006.

Eur J Public Health 2011; 21: 620–626.

25.

Jarrin

, Pantazis

, Gill

M.J.

CASCADE Collaboration in EuroCoord. Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia.

Clin Infect Dis 2012; 54: 111–118.

26.

The Antiretroviral Therapy Cohort Collaboration (ART-CC).

Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States.

Clin Infect Dis 2013; 56: 1800–1809.

27.

Martin

L.J.

, Houston

, Yasui

, Wild

T.C.

, Saunders

L.D.

All-cause and HIV-related mortality rates among HIV-infected patients after initiating highly active antiretroviral therapy: the impact of Aboriginal ethnicity and injection drug use.

Can J Public Health 2011; 102: 90–96.

28.

Oramasionwu

C.U.

, Brown

C.M.

, Lawson

K.A.

, Ryan

, Frei

C.R.

Evaluating HIV/AIDS disparities for blacks in the United States: a review of antiretroviral and mortality studies.

J Natl Med Assoc 2009; 101: 1221–1229.

29.

French

A.L.

, Gawel

S.H.

, Hershow

Trends in mortality and causes of death among women with HIV in the United States: a 10-year study.

J Acquir Immune Defic Syndr 2009; 51: 399–406.

30.

Feldman

J.G.

, Minkoff

, Schneider

M.F.

Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study.

Am J Public Health 2006; 96: 1060–1065.

31.

May

M.T.

, Hogg

R.S.

, Justice

A.C.

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

Int J Epidemiol 2012; 41: 1807–1820.